Browse the evidence

Concurrent exposure to liraglutide and a GIPRA is hypothesized to produce fewer GI adverse effects than exposure to liraglutide alone.

This suggests a potential strategy for reducing side effects in patients using liraglutide.

There is limited literature on the impact of weight loss medications for plastic surgeons and their patients.

Plastic surgeons need to seek more information on the effects of these medications.

Plastic surgeons must understand the indications, contraindications, and perioperative management of weight loss medications.

Surgeons should educate themselves on these medications to ensure safe practices.

In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Tirzepatide may also be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

There is much more variation in total, activity, and basal energy expenditure among males compared to females.

Practitioners should consider the greater variability in energy expenditure among males when designing interventions.

Variation in total energy expenditure decreases with aging, more rapidly in males.

Interventions may need to adjust for age-related changes in energy expenditure variability.

The consumption of saturated fat (SFA) is not significantly associated with cardiovascular disease (CVD) risk, events, or mortality.

Practitioners can consider including SFA from nutrient-dense foods in diets without fear of increasing CVD risk.

There is no scientific ground to demonize saturated fat as a cause of cardiovascular disease.

Health professionals can reassess dietary guidelines that restrict SFA without evidence of harm.

Beneficial effects of replacing saturated fat with polyunsaturated or monounsaturated fat or carbohydrates remain elusive.

Dietary recommendations should be cautious about promoting replacements for SFA without clear evidence of benefit.

Semaglutide showed a favorable hepatic safety profile with no discontinuations due to liver enzyme elevations.

Semaglutide can be considered safe for liver health in the studied population.

Current guidelines provide limited recommendations for the medical management of patients with obesity-related HFpEF.

Healthcare providers may need to seek additional resources for managing obesity-related HFpEF.

The role of GLP-1 receptor agonists in obesity-related HFpEF remains unclear.

Further research is needed to clarify the role of GLP-1 receptor agonists in managing obesity-related HFpEF.

Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.

GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.

A single-site measure of muscle shape does not adequately capture the effects of exercise training interventions.

Multiple measurement sites should be used to assess training effects accurately.

Nineteen approved and pending Medicaid Section 1115 waivers address nutrition, with eleven submitted or approved since 2021.

Practitioners should be aware of the increasing number of waivers addressing nutrition in Medicaid.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

GLP-1-RAs are known to delay gastric emptying.

Understanding the effect of GLP-1-RAs on gastric emptying is crucial for perioperative management.

There was no difference in mean total body weight change between IBD and non-IBD cohorts after semaglutide initiation.

Weight loss outcomes with semaglutide appear consistent regardless of IBD status.

Common complications associated with GLP-1 RA treatment include nausea, constipation, abdominal pain, and vomiting.

Healthcare providers should monitor patients for these common side effects when prescribing GLP-1 RA.

ω-3-PL/FFA was well tolerated with a safety profile similar to that of placebo.

Practitioners can confidently recommend ω-3-PL/FFA as a safe option for patients.

Obstructive sleep apnea is a common comorbidity in individuals with obesity.

Healthcare providers should be aware of the high prevalence of obstructive sleep apnea in obese patients.

GIP accounts for 60% to 80% of the postprandial insulin response.

Understanding GIP's role can help in managing postprandial insulin levels.

GIP is overexpressed in obese individuals, which may exacerbate insulin resistance.

Addressing GIP levels may be important in treating obesity-related insulin resistance.

The safety profile of tirzepatide was broadly similar across BMI and age subgroups, but drug discontinuation due to adverse events was higher in participants aged ≥ 65 years.

While generally safe, practitioners should monitor older patients closely when prescribing tirzepatide.